HD1916
Phase 3Small molecule
HD1916 is one of 44 small molecule programs targeting Obesity. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Elecoglipron
AstraZenecaPhase 3
HD1916
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obesity1 trial
Semaglutide in Treatment of Obesity
Active, not recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT06604624·462 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HD1916. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details